Compare Quest Diagnostics Inc (DGX) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Lemonade Inc — how do they compare? Quest Diagnostics Inc trades at $231.03 (market cap $25.48B), while Lemonade Inc trades at $46.61 (market cap $3.63B). The key difference: Quest Diagnostics Inc is far larger — about 7× Lemonade Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Lemonade Inc for 27 Days on average.
| DGX | LMND | |
|---|---|---|
Market Cap | $25.48B | $3.63B |
Volume | 941,866 | 1,544,794 |
Sector | Health | Financials |
52-Week High | $247.45 | $96.57 |
52-Week Low | $173.49 | $43.91 |
Typical Hold Time | 56 Days | 27 Days |
Enterprise Value | $31.23B | $3.49B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Lemonade (LMND) trades at $46.83, up 1.14% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth is accelerating, reaching $738M in 2025, with a narrowing net loss margin from -116% in 2022 to -22.4% in 2025. The company is expanding geographically and product-wise, supported by AI-driven efficiency, targeting EBITDA profitability by late 2026.
The outlook is mixed: strong growth and path to profitability present opportunity, but persistent losses, high valuation multiples, and bearish technicals pose risks. The consensus price target of $67 implies significant upside if execution continues, but investor sentiment remains divided given the stock's high volatility and unprofitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
